Hemab Therapeutics (NASDAQ:COAG) Reaches New 52-Week High – Here’s What Happened

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price hit a new 52-week high during trading on Thursday . The company traded as high as $52.29 and last traded at $51.07, with a volume of 38258 shares changing hands. The stock had previously closed at $50.09.

Wall Street Analysts Forecast Growth

A number of research firms have commented on COAG. Wedbush restated an “outperform” rating and issued a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a research note on Monday, July 13th. Jefferies Financial Group raised their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright upped their price objective on Hemab Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

Hemab Therapeutics Stock Up 1.2%

The firm has a market capitalization of $2.37 billion and a price-to-earnings ratio of -2.11. The firm has a 50 day moving average of $35.62.

Hemab Therapeutics (NASDAQ:COAG) last posted its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were acquired at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the purchase, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired 120,206 shares of company stock valued at $2,994,826 in the last quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.